7
Participants
Start Date
June 1, 2024
Primary Completion Date
February 28, 2025
Study Completion Date
May 31, 2028
Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001)
"Investigational PET agents will be synthesized at UCSD and administered to subjects according to the local institutional guidelines. IND applications for these agents are linked with the IND application for the study product, CT1-DAP001. The IND applications for the PET radiopharmaceuticals contains the manufacturing method, specifications, quality testing, clinical usage, and safety and efficacy information for individual PET agents.~Investigational Cell Injector Suniviion needle: The investigational instrument will be used to administer dopaminergic progenitors into the putamen. After aspirating cells, the instrument will be attached to a Leksell stereotactic frame to administer the cells into the brain."
RECRUITING
University of California, San Diego, La Jolla
Sumitomo Pharma America, Inc.
INDUSTRY
Kyoto University
OTHER
Sumitomo Pharma Co., Ltd.
INDUSTRY
CiRA Foundation
UNKNOWN
University of California, San Diego
OTHER